

Attorney Docket No. A116 US

Applicants

Stephen M. Strittmatter, et al.

RECEIVED

Title

NOGO RECEPTOR HOMOLOGS

APR 0 1 2003

Filed Date

October 6, 2001

FECH CENTER 1600/2905

Application No.

09/972,546

Confirmation No. 4440

Group Art Unit

1647

Examiner

Christopher J. Nichols

Express Mail mailing label number <u>EV242443138US</u>

Date of Deposit March 27, 2003

I hereby certify that this paper/fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Hon. Commissioner for Patents, P.O. Box 2327, Arlington, Virginia 22202.

Encls.

- (1) Transmittal Letter (in dupl.);
- (2) Reply to Restriction Requirement; and
- (3) Postcard.

A116 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Christopher J. Nichols

Group Art Unit

1647

Applicants

Stephen M. Strittmatter, et al.

RECEIVED

Application No.

09/972,546

APR 0 1 2003

Confirmation No.

4440

TECH CENTER 1600/2900

Filed

October 6, 2001

For

NOGO RECEPTOR HOMOLOGS

New York, New York March 27, 2003

Hon. Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Reply to Restriction Requirement; to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

- [X] A fee for additional claims is not required.
- [] A fee for additional claims is required.

The additional fee has been calculated as shown below:

	Claims Remaining After Amendment	Highest Number Previously Paid for		Present Extra		Fees
TOTAL CLAIMS	58	- 58*	= .	0	x \$18	= \$0.00
INDEPENDENT CLAIMS	7	7**	=	0	x \$84	= \$0.00
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM	,				+ \$280	= \$0.00
* If less than 20, inser	t 20.				TOTAL	\$0.00
** If less than 3, inser	t 3.					
[] A check in the amount of \$ in payment of the filing fee is transmitted herewith.						
[X] The Director is required under 37 C.F credit any overpaymentransmittal letter is transmittal	R. § 1.16, in cont of same, to de	posit Account N	e paper(s	s) tran	smitted he	rewith, or
[] Please charge S A duplicate copy of th		osit Account No.			ayment of	the filing fee.
EXTENSION FEE						
[] The following extension fee for responsion fee for responsion fee for responsion fee [] \$1450.00 extension \$1970.00 within fifth the second	onse within first onse within secone one for response value for response value.	ond month pursua within third mont e within fourth n	to 37 C. ant to 37 h pursua nonth pu	F.R. § C.F.R int to :	1.136(a); R. § 1.136(a); 37 C.F.R. §	[]\$410.00 a); §1.136(a);

[] A check in the amount of [] \$110.00; [] \$410.00; [] \$820.00; [] \$1450.00; [] \$1970.00 in payment of the extension fee is transmitted herewith.
[X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.
Please charge the [] \$110.00; [] \$410.00; [] \$930.00; [] \$1450.00; [] \$1970.00; extension fee to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794) Karen Mangasarian (Reg. No. 43,772) Attorneys for Applicants Grant Kalinowski (Reg. No. 48,314)

Agent for Applicants

FISH & NEAVE Customer No. 1473 1251 Avenue of the Americas New York, New York 10020-1104

Tel.: (212) 596-9000 Fax: (212) 596-9090



A116 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Christopher J. Nichols

Group Art Unit

1647

Applicants

Stephen M. Strittmatter, et al.

RECEIVED

Application No.

09/972,546

APR 0 1 2003

Confirmation No.

4440

TECH CENTER 1600/2900

Filed

October 6, 2001

For

NOGO RECEPTOR HOMOLOGS

New York, New York March 27, 2003

Hon. Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

REPLY TO RESTRICTION REQUIREMENT

Sir:

This is in reply to the February 27, 2003 Office Action in the above-identified application. The period for replying to the Office Action extends up to and includes March 27, 2003. Thus, this reply is timely filed.

THE RESTRICTION

The Examiner has required restriction of the claims of this application under 35 U.S.C. § 121 into one of the following eight groups:

Group I: Claims 1-10 and 22, drawn to a method for producing a polypeptide comprising an isolated nucleic acid molecule and vectors and cells comprising the same;

Group II: Claims 11-21 and 24, drawn to an isolated polypeptide and pharmaceutical compositions comprising the same;

Group III: Claims 23 and 25, drawn to an antibody immunospecific for a polypeptide and pharmaceutical compositions and kits comprising the same;

Group IV: Claim 26, drawn to a method of decreasing inhibition of axonal grown of a CNS neuron, comprising the step of contacting the neuron with an effective amount of a polypeptide;

Group V: Claim 27, drawn to a method of treating a central nervous system disease, disorder or injury, comprising administering to a mammal an effective amount of a polypeptide;

Group VI: Claim 28, drawn to a method of decreasing inhibition of axonal growth of a CNS neuron comprising the step of contacting the neuron with an effective amount of an antibody;

Group VII: Claim 29, drawn to a method of treating a central nervous system disease, disorder or injury, comprising administering to a mammal an effective amount of an antibody; and

Group VIII: Claim 30, drawn to a method of identifying a molecule that binds a polypeptide.

The Examiner asserts that the inventions encompassed by Groups I-VIII are directed to different methods and different products, which constitute patentably distinct inventions.

In response to this requirement, applicants elect the subject matter of Group I (claims 1-10 and 22), without traverse, for further prosecution in this application. These claims are directed to methods for producing a polypeptide, as described in the Office Action, as well as to isolated nucleic acid molecules and vectors and host cells comprising the isolated nucleic acid molecules.

The Examiner further asserts that each of inventions I-VIII encompasses, in part, additional inventions comprising particular, patentably distinct, products and that a separate election is required from inventions A-H below:

Group A: SEQ ID NO: 2;

Group B: SEQ ID NO: 4;

Group C: SEQ ID NO: 5;

Group D: SEQ ID NO: 11;

Group E: SEQ ID NO: 14;

Group F: SEQ ID NO: 17;

Group G: SEQ ID NO: 18; and

Group H: SEQ ID NO: 19.

In response to this requirement, applicants further elect the subject matter of Group A (i.e. claims 1-20 and 22 of Group I as they pertain to SEQ ID NO: 2), without traverse, for further prosecution in this application.

Applicants make the elections of both Group I and Group A claims expressly without waiver of their right to file for and obtain claims directed to the non-elected subject matter in divisional or continuing applications claiming priority and benefit herefrom, or from a related application, under U.S.C. § 120.

CONCLUSION

In view of the above, applicants request that the Examiner examine the pending claims in this application.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794) Karen Mangasarian (Reg. No. 43,772)

Attorneys for Applicants

Grant Kalinowski (Reg. No. 48,314)

Agent for Applicants

FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000 Fax: (212) 596-9090